Sanofi sees 'strong strategic' fit with U.S. Medivation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Raises Price Target on Regeneron (REGN) Following 1Q Report
May 6, 2016 9:08 AM EDTLeerink Partners reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $530.00 (from $523.00), following the company's 1Q earnings report. Total revenue beat consensus by 2% driven by higher collaboration revenue, and revenue grew by 38% compared to Q1 2015 and by 9% QoQ. The companys earnings fell short of consensus based on higher than expected SG&A and taxes. Pro forma EPS was $2.57 below consensus of $2.68.
Analyst Geoffrey Porges... More
Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform
May 5, 2016 3:25 PM EDTBaird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $526.00), following the company's 1Q earnings report. EPS of $2.57 was reported in-line with expectations. Baird continues to believe that the copmant can deliver growth over the next few... More
